Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Price Arbitration In Medicare: MedPAC Supportive But Congress Running Out Of Time

Executive Summary

In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.

You may also be interested in...



As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate

Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.

US Drug Pricing Reforms: ASCO Hears About Bargaining Chips And Baby Steps

Former long-time congressional health staffer Rodney Whitlock discusses the status of prescription drug pricing reform policies in the administration and congress at the American Society for Clinical Oncology annual meeting.

Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal

Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel